[125I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [18F]Flotaza and [125I]IBETA in Postmortem Human Alzheimer's Disease.

Neurol Int · 2024 · PMC11054302 · PMID 38668128

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Despite the large size of antibodies leading to low uptake, their high affinity for Aβ plaques with therapeutic implications makes imaging highly significant [ 32 , 33 , 34 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

[&lt;sup&gt;125&lt;/sup&gt;I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [&lt;sup&gt;18&lt;/sup&gt;F]Flotaza and [&lt;sup&gt;125&lt;/sup&gt;I]IBETA in Postmortem Human Alzheimer's Disease.

The sentences

[<sup>125</sup>I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [<sup>18</sup>F]Flotaza and [<sup>125</sup>I]IBETA in Postmortem Human Alzheimer's Disease.